Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian firm presses on with COPD (chronic obstructive pulmonary disease) theranostic

This article was originally published in Clinica

Executive Summary

Australian company Pharmaxis has completed the enrolement phase of a clinical trial of its Aridol theranostic test in patients with chronic obstructive pulmonary disease (COPD). The test is already approved in Australia to identify asthma patients who will respond to inhaled steroid therapy, by detecting "steroid responsive inflammation".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel